https://scholars.lib.ntu.edu.tw/handle/123456789/548478
標題: | Sertoli-Leydig cell tumors of the ovary: A Taiwanese Gynecologic Oncology Group study | 作者: | Weng C.-S. Chen M.-Y. Wang T.-Y. Tsai H.-W. Hung Y.-C. Yu K.-J. YING-CHENG CHIANG Lin H. Lu C.-H. Chou H.-H. |
關鍵字: | Chemotherapy; Ovary; Sertoli-Leydig cell tumor; Sex cord-stromal tumors; Taiwanese Gynecologic Oncology Group (TGOG) study | 公開日期: | 2013 | 卷: | 52 | 期: | 1 | 起(迄)頁: | 66-70 | 來源出版物: | Taiwanese Journal of Obstetrics and Gynecology | 摘要: | Objective: To report the natural history and prognosis of the uncommon Sertoli-Leydig cell tumor (SLCT) of the ovary. Materials and Methods: A 20-year retrospective review was conducted by the Taiwanese Gynecologic Oncology Group (TGOG), including nine tertiary medical centers from different regions in Taiwan. The medical records for 40 cases of ovarian SLCT were collected. Pathology reviews were carried out by a panel of expert pathologists. Results: After pathological review, 17 patients were subsequently excluded because the pathology slides were unavailable in five cases, and discrepant results from the initial diagnosis were found in 12 cases (34%). For the remaining 23 patients, the median age was 41 years. The most common symptom was irregular vaginal bleeding followed by an abdominal mass or amenorrhea. Most of the tumors were unilateral and confined to the right ovary, with an average size of 8.2 cm. Preoperative serum markers were available for 12 patients and were elevated for three patients. All patients underwent primary surgery. Six patients accepted adjuvant chemotherapy, and bleomycin, etoposide, and cisplatin were used in four of them. Clinical follow-up information was available in 21 patients with a median of 19 months. Eighty-two percent of patients were alive and free of disease up to the date of the last follow-up. Two patients died of the disease. Conclusion: This study demonstrates the extreme rarity of ovarian SLCT in Taiwan. Histological discordance between the diagnosis and central review proves the need for expertise review before treatment. For an improved understanding of the biological behavior and treatment strategy for this unique tumor, international collaboration is imperative. ? 2013. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878020503&doi=10.1016%2fj.tjog.2012.03.001&partnerID=40&md5=74c891a542c4b6fa5472d3c489639b03 https://scholars.lib.ntu.edu.tw/handle/123456789/548478 |
ISSN: | 1028-4559 | DOI: | 10.1016/j.tjog.2012.03.001 | SDG/關鍵字: | bleomycin; cisplatin; etoposide; abdominal mass; adolescent; adult; aged; amenorrhea; androblastoma; article; cancer chemotherapy; cancer prognosis; cancer surgery; clinical article; female; follow up; human; medical record review; medical society; ovary tumor; Taiwan; tumor volume; vagina bleeding; Adolescent; Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Sertoli-Leydig Cell Tumor; Taiwan; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。